Antibiotic treatment of tuberculosis takes≥ 6 months, putting a major burden on patients and
health systems in large parts of the world. Treatment beyond 2 months is needed to prevent …

Background Interim treatment outcomes at 6-months for multidrug-resistant tuberculosis
(MDR-TB) treatment are among the most basic performance monitoring and key evaluation …

Evaluating therapy efficacy is crucial for patients with tuberculosis (TB), especially those with
drug-resistant tuberculosis (DR-TB). The World Health Organization currently recommends …

Background Sputum smear and culture conversions are an important indicator of treatment
efficacy and help to determine treatment duration in multidrug resistant tuberculosis (MDR …

Background Few prospective cohort studies, none in China, have investigated the
relationship between treatment outcomes of multidrug-resistant tuberculosis (MDR-TB) …

BACKGROUND: Brazil ranks 14th worldwide in the number of TB cases and 19th in terms of
TB-HIV co-infected cases. This study aims at identifying clinical and demographic factors …

Untreated active tuberculosis (TB) has a very high long-term mortality. Treatment of TB
reduces mortality dramatically and should maximize cure, preventing ongoing transmission …

Purpose: Multidrug-resistant tuberculosis (MDR-TB) requires long-term treatment, has a high
fatality rate, and constitutes a global threat. Earlier detection of treatment failure is required …

Аннотация В обзоре проанализировано 70 источников литературы. Представлены
актуальные данные о препаратах, сроках, показаниях к применению, эффективности и …

BACKGROUND: Bedaquiline (BDQ) is widely used in the treatment of rifampicin-resistant TB
(RR-TB). However, resistance to BDQ is now emerging. There are no standardised …